Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X

Harmony Biosciences (HRMY) has marked its Phase 3 study of cannabidiol in children, adolescents and young adults with Fragile X syndrome as COMPLETED on ClinicalTrials.gov. The registry record, filed under NCT04977986, was last updated on 1 September 2026. No results, endpoints or efficacy data are included in the entry.

The study is listed as a Phase 3 clinical study with Harmony Biosciences Management, Inc. as the sponsor. The indication is recorded as Fragile X Syndrome (FXS), a genetic condition for which there is no approved disease-specific pharmacological treatment in the United States.

A status change to COMPLETED means enrolment and follow-up under the protocol have finished. It does not in itself indicate whether the trial met its primary endpoint; that information typically follows in a separate company disclosure or scientific presentation.

For Harmony, the trial sits alongside the company's broader effort to broaden its pipeline beyond its established sleep-disorder franchise into rare neurological and neurodevelopmental conditions. A Phase 3 readout in Fragile X would be the gating factor for any regulatory filing.

Investors following the name will be watching for a topline data announcement, since the registry update alone conveys only the administrative fact that the study has concluded. Until Harmony publishes results, the clinical and commercial significance of the completion remains unquantified.

This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.